Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease, Hospital
Therapuetic Areas:Nephrology / Urology, Other
Healthy:No
Age Range:18 - Any
Updated:2/3/2018
Start Date:October 2015
End Date:December 2019
Contact:Nikita Chavda, BSc
Email:ChavdaN@smh.ca

Use our guide to learn which trials are right for you!

STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)

The objectives of this trial are to determine whether, in critically ill patients with severe
acute kidney injury (AKI), randomization to accelerated initiation of renal replacement
therapy (RRT), compared to standard initiation, leads to:

1. Improved survival (primary outcome); and

2. Recovery of kidney function (principal secondary outcome), defined as independence from
RRT at 90 days

Acute kidney injury (AKI) is a common and devastating complication of critical illness. Once
AKI is established, treatment is largely supportive and no intervention has been found to
restore kidney function or improve overall survival. Renal replacement therapy (RRT), usually
in the form of hemodialysis, is frequently needed to manage patients with severe AKI. Such
patients have an in-hospital mortality that consistently exceeds 50% with delays in RRT
initiation implicated as a possible contributor. A recent meta-analysis suggested that
earlier initiation of RRT may improve survival, but this is based on data derived
overwhelmingly from observational studies. The investigators recently completed a
multi-centre randomized controlled pilot trial that confirmed the feasibility of allocating
patients to two different strategies of RRT initiation. Patient recruitment and follow-up, as
well as patient safety, were successfully demonstrated during the pilot phase of this
research program. The optimal timing of RRT initiation is an existing knowledge gap and a
clear priority for investigation.

Inclusion Criteria:

1. Age ≥ 18 years

2. Admission to an intensive care unit (ICU)

3. Evidence of kidney dysfunction [serum creatinine ≥100 µmol/L (women) and ≥ 130 µmol/L
(men)]

4. Evidence of severe AKI defined by at least 1 of the following 3 criteria:

i) ≥ 2-fold increase in serum creatinine from a known pre-morbid baseline or during
the current hospitalization; OR ii) Achievement of a serum creatinine ≥ 354 µmol/L
with evidence of a minimum increase of 27 µmol/L from pre-morbid baseline or during
the current hospitalization; OR iii) Urine output < 6.0 mL/kg over the preceding 12
hours

Exclusion Criteria:

1. Serum potassium > 5.5 mmol/L

2. Serum bicarbonate < 15 mmol/L

3. Presence of a drug overdose that necessitates initiation of RRT

4. Lack of commitment to ongoing life support (including RRT)

5. Any RRT within the previous 2 months (either acute or chronic RRT)

6. Kidney transplant within the past 365 days

7. Known pre-hospitalization advanced chronic kidney disease, defined by an estimated
glomerular filtration rate < 20 mL/min/1.73 m2

8. Presence or clinical suspicion of renal obstruction, rapidly progressive
glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial
nephritis

9. Clinician(s) caring for patient believe(s) that immediate RRT is mandated

10. Clinician(s) caring for patient believe(s) that deferral of RRT initiation is mandated

- at their discretion, clinicians may administer a bolus of intravenous furosemide
(ie, "furosemide stress test") and evaluate the subsequent urine output to help
guide decision making regarding the likelihood of AKI progression
We found this trial at
9
sites
Rochester, Minnesota 55905
Principal Investigator: Kianoush Kashani
?
mi
from
Rochester, MN
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Ashita Tolwani
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
1.800.422.9567
Principal Investigator: Harold Szerlip
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Azra Bihorac
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Sairah Sharif
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
1 Drummond Street North
Ballarat, 3350
Principal Investigator: Angus Richardson
?
mi
from
Ballarat,
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Jay Koyner
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Lexington, Kentucky 40536
Principal Investigator: Javier Neyra Lozano
?
mi
from
Lexington, KY
Click here to add this to my saved trials
164 Summit Ave
Providence, Rhode Island 02906
(401) 793-2500
Principal Investigator: Sairah Sharif
Miriam Hospital The Miriam Hospital is a private, not-for-profit hospital, with a history of providing...
?
mi
from
Providence, RI
Click here to add this to my saved trials